- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Dna Binding Protein.
Displaying page 1 of 1.
EudraCT Number: 2014-004902-13 | Sponsor Protocol Number: D0490C00023 | Start Date*: 2015-04-09 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positr... | |||||||||||||
Medical condition: Multiple system atrophy (MSA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002534-23 | Sponsor Protocol Number: 3124001 | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | |||||||||||||
Medical condition: Metastatic castration-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Ongoing) GB (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002843-81 | Sponsor Protocol Number: 057 | Start Date*: 2020-01-07 |
Sponsor Name:IMEA | ||
Full Title: Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication | ||
Medical condition: HIV-1-infected patient Age > 65 years old Plasma HIV RNA ≤ 50 copies/mL for ≥ 6 months: one blip between 50 et 200 cp/ml is allowed in the last 6 months before screening. Currently receiving an ant... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019374-32 | Sponsor Protocol Number: CP-4-003 | Start Date*: 2010-07-15 | |||||||||||
Sponsor Name:ModigeneTech Ltd. | |||||||||||||
Full Title: A Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA) | |||||||||||||
Medical condition: Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) SI (Completed) CZ (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005604-35 | Sponsor Protocol Number: APEC1621B | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:National Cancer Institute (NCI) | |||||||||||||
Full Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations | |||||||||||||
Medical condition: Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002204-33 | Sponsor Protocol Number: C32322 | Start Date*: 2007-03-02 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose... | |||||||||||||
Medical condition: Relapsing forms of multiple slerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000785-37 | Sponsor Protocol Number: GS-US-320-1092 | Start Date*: 2016-08-26 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004241-32 | Sponsor Protocol Number: EDOLAS | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI | |||||||||||||
Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression | |||||||||||||
Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000099-27 | Sponsor Protocol Number: HEAT01 | Start Date*: 2017-04-26 | |||||||||||
Sponsor Name:The Department of Urology | |||||||||||||
Full Title: Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial | |||||||||||||
Medical condition: Metastisc castration resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002392-27 | Sponsor Protocol Number: A5481003 | Start Date*: 2009-04-06 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE PLUS PD 0332991 (ORAL CDK 4/6 INHIBITOR) AND LETROZOLE SINGLE AGENT FOR THE FIRST-LINE TREATMEN... | |||||||||||||
Medical condition: Advanced Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IE (Completed) HU (Completed) DE (Completed) FR (Completed) IT (Completed) ES (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002890-71 | Sponsor Protocol Number: RifaxNK150612 | Start Date*: 2012-08-16 | |||||||||||
Sponsor Name:Flemming Bendtsen | |||||||||||||
Full Title: Intestinal decontamination with rifaximin. Effects on the inflammatory and circulatory state in patients with cirrhosis and ascites - A randomised controlled clinical study | |||||||||||||
Medical condition: Liver cirrhosis of any etilogy, complicated by decompensation and classified as Child-Pugh B or C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004195-19 | Sponsor Protocol Number: CREPATS10 | Start Date*: 2020-07-07 | |||||||||||
Sponsor Name:Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS) | |||||||||||||
Full Title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma vire... | |||||||||||||
Medical condition: HIV disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016720-31 | Sponsor Protocol Number: 250901 | Start Date*: 2010-06-09 | |||||||||||
Sponsor Name:Baxter Innovations GmbH [...] | |||||||||||||
Full Title: BAX 326 (recombinant Factor IX): A Phase 1/3 Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, Immunogenicity in Previously Treated Patients with Severe (FIX... | |||||||||||||
Medical condition: Previously treated patients with severe (FIX level < 1%) or moderately severe (FIX level ≤ 2%) hemophilia B. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001205-23 | Sponsor Protocol Number: OVERLORD-MS | Start Date*: 2020-07-10 | |||||||||||
Sponsor Name:Helse Bergen HF, Haukeland University Hospital | |||||||||||||
Full Title: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) | |||||||||||||
Medical condition: Remitting Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005573-21 | Sponsor Protocol Number: A4021004 | Start Date*: 2007-01-26 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE... | |||||||||||||
Medical condition: Hormone receptor positive advanced breast cancer in postmenopausal women. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) NL (Temporarily Halted) GB (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000558-37 | Sponsor Protocol Number: ARQ092-103 | Start Date*: 2017-02-22 | |||||||||||
Sponsor Name:ArQule, Inc. | |||||||||||||
Full Title: A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway | |||||||||||||
Medical condition: subjects (at least 6 years) suffering from diseases overgrowth and vascular anomalies with genetic alterations of the PI3K / AKT pathway. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) FR (Ongoing) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.